ERBB2 and breast cancer: The primary tumor location was correctly identified with 71% accuracy, and since each molecular subtype induced different stimuli that affected platelet profile, the analyses, based on TEP profiles, successfully distinguished between BC patients who had HER2-amplified, PIK3CA-mutant, or triple-negative phenotypes.